An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
The safety profile was described as manageable, though not without notable toxicities
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
While overall survival data remain immature, the results pointed to a favourable trend.
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival
This marks one of the most closely watched oncology readouts at this year’s medical congress
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
Subscribe To Our Newsletter & Stay Updated
